Acute care syndromic testing market seen reaching $8.3 billion by 2030

The acute care syndromic testing market is projected to grow from $4.59 billion in 2025 to $5.17 billion in 2026, then reach about $8.3 billion by 2030, according to a new forecast from The Business Research Company. The report points to rising infectious disease cases, AI-enabled panels and point-of-care molecular systems as key drivers.

Why it matters: - Acute care syndromic testing helps hospitals and emergency departments identify multiple pathogens fast from a single specimen. - Faster results can support quicker treatment decisions, improve clinical outcomes and reduce hospital stays. - The forecast points to continued demand in critical care settings as infectious disease pressure rises and hospitals expand rapid testing capacity.

What happened: - The Business Research Company released its Acute Care Syndromic Testing Market Report 2026 on July 23, 2026. - The market was valued at $4.59 billion in 2025. - The market is projected to grow to $5.17 billion in 2026. - The forecast puts the market at $8.3 billion by 2030. - The report covers market size, trends, global forecasts and regional growth prospects. - The report offers a free sample and the full market report.

The details: - Acute care syndromic testing is a molecular diagnostic method that detects multiple pathogens from one patient specimen. - The testing is used mainly in emergency and critical care units. - The market posted a 12.8% CAGR in the move from 2025 to 2026. - The market is expected to grow at a 12.5% CAGR through 2030. - Growth drivers include rapid infection diagnosis, ICU expansion, outbreak preparedness, greater use of molecular diagnostics and workflow improvements in critical care. - Future demand is expected to be supported by AI-powered syndromic panels, emergency testing services, antimicrobial stewardship efforts, broader access to point-of-care molecular systems and pandemic readiness. - Expected product and workflow trends include rapid multiplex pathogen detection, multi-disease panels from a single sample, faster clinical decision support and shorter turnaround times. - The report says rising infectious disease cases are a major market driver. - UK Health Security Agency data from February 2024 showed influenza positivity rising to 16.6% in week 4 from 14.0% the prior week. - The same UK data showed increased influenza-like illness consultations and hospitalizations. - Molecular diagnostic advances and AI integration are shaping the market's growth. - AI-enabled panels can improve speed and accuracy of pathogen detection. - Point-of-care molecular devices are increasingly used at the bedside and in emergency departments.

Between the lines: - The forecast suggests acute care testing is shifting from a specialized diagnostic tool to a more embedded part of emergency workflow. - AI and point-of-care systems appear to be reducing the gap between sample collection and clinical action. - The emphasis on infectious disease readiness reflects how hospitals are treating testing capacity as part of broader preparedness planning, not just routine care.

What's next: - North America is expected to remain a leading market because of advanced healthcare infrastructure and broad adoption of innovative diagnostics. - Asia-Pacific is expected to post strong growth as healthcare systems improve and infectious disease burdens increase. - The report highlights continued interest in market scoring tools, TAM analysis, forecasting dashboards and trend analysis for buyers and investors. - The company also provided contact details for expert inquiries and promoted its social channels.